[go: up one dir, main page]

AR056137A1 - Un conjugado peptido inmunoglobulina y su uso como antiviral - Google Patents

Un conjugado peptido inmunoglobulina y su uso como antiviral

Info

Publication number
AR056137A1
AR056137A1 ARP060104561A ARP060104561A AR056137A1 AR 056137 A1 AR056137 A1 AR 056137A1 AR P060104561 A ARP060104561 A AR P060104561A AR P060104561 A ARP060104561 A AR P060104561A AR 056137 A1 AR056137 A1 AR 056137A1
Authority
AR
Argentina
Prior art keywords
immunoglobulin
peptide
amino acid
antiviral
terminal
Prior art date
Application number
ARP060104561A
Other languages
English (en)
Inventor
Stephan Fischer
Erhard Kopetzki
Suryanarayana Sankuratri
Ralf Schumacher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR056137A1 publication Critical patent/AR056137A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica que contiene al conjugado y su uso para el tratamiento de infecciones virales, entre otras HIV Reivindicacion 1: Un conjunto péptido-inmunoglobulina que se caracteriza en que a) dicha inmunoglobulina consiste en dos cadenas pesadas o dos cadenas pesadas y dos cadenas ligeras, b) dicha inmunoglobulina no es una inmunoglobulina funcional, c) dicho conjugado tiene la siguiente formula inmunoglob ulina-[péptido]n, en la que n es un numero entero de entre 2 y 8, d) un enlace peptídico conjuga el aminoácido carboxi-terminal del péptido con el aminoácido amino-terminal de la cadena inmunoglobulina o el aminoácido carboxi-terminal de la cadena inmunoglobulina con el aminoácido amino-terminal del péptido.
ARP060104561A 2005-10-21 2006-10-19 Un conjugado peptido inmunoglobulina y su uso como antiviral AR056137A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05023002 2005-10-21

Publications (1)

Publication Number Publication Date
AR056137A1 true AR056137A1 (es) 2007-09-19

Family

ID=35809600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104561A AR056137A1 (es) 2005-10-21 2006-10-19 Un conjugado peptido inmunoglobulina y su uso como antiviral

Country Status (13)

Country Link
US (1) US20070148180A1 (es)
EP (1) EP1940882A1 (es)
JP (1) JP2009512655A (es)
KR (1) KR20080070014A (es)
CN (1) CN101291956A (es)
AR (1) AR056137A1 (es)
AU (1) AU2006303438A1 (es)
BR (1) BRPI0617511A8 (es)
CA (1) CA2625332A1 (es)
IL (1) IL190552A0 (es)
NO (1) NO20081704L (es)
TW (1) TW200722436A (es)
WO (1) WO2007045463A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
KR101280704B1 (ko) 2007-10-12 2013-07-01 에프. 호프만-라 로슈 아게 다수의 핵산으로부터의 단백질 발현
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
TW201129379A (en) 2009-11-20 2011-09-01 Amgen Inc Anti-Orai1 antigen binding proteins and uses thereof
KR20130097747A (ko) 2010-08-10 2013-09-03 암젠 인크 표적 항체에 대한 중화 항체의 검출을 위한 이중 기능 시험관내 표적 결합 분석평가
CA2885176C (en) * 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
EA201370161A1 (ru) 2011-01-18 2013-12-30 Амген Инк. НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ
BR112014014418A2 (pt) * 2011-12-15 2019-09-24 Nat Res Council Canada proteínas de fusão fc de receptor igf solúvel e usos das mesmas
CA2864702A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
MX377591B (es) 2014-10-15 2025-03-10 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
KR20190038456A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE69334070T2 (de) * 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6207153B1 (en) * 1996-05-22 2001-03-27 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2002026833A1 (en) * 1999-07-06 2002-04-04 University Of Tennessee Corporation Compositions and methods for the endocytic presentation of immunosuppressive factors
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus

Also Published As

Publication number Publication date
BRPI0617511A2 (pt) 2015-07-07
CA2625332A1 (en) 2007-04-26
AU2006303438A1 (en) 2007-04-26
WO2007045463A1 (en) 2007-04-26
EP1940882A1 (en) 2008-07-09
KR20080070014A (ko) 2008-07-29
BRPI0617511A8 (pt) 2018-04-24
JP2009512655A (ja) 2009-03-26
NO20081704L (no) 2008-06-05
TW200722436A (en) 2007-06-16
US20070148180A1 (en) 2007-06-28
CN101291956A (zh) 2008-10-22
IL190552A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
PE20060880A1 (es) Conjugados de polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
AR080216A2 (es) Composiciones farmaceuticas que contienen una proteina de fusion de vih
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
EA200400962A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
HN2002000319A (es) Benzamida, heteroarilamida y amidas inversas
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
EP1507556A4 (en) CALICHEAMICINE DERIVATIVE VECTOR-TYPE CONJUGATES
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
CL2004000270A1 (es) Compuestos derivados de pirazol, sus sales de adicion acidas,trastornos de vih y virus geneticamente relacionados. hidratos, solvatos; composiciones farmaceuticas; y su uso en el tramiento de trastornos del vih y virus geneticamente relacionados.
UY27329A1 (es) Champues con alcohol de behenilo
PE20120021A1 (es) Mutantes fgf21
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
CO6241131A2 (es) Vacuna
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
DE602005008996D1 (de) Radiofluorierte peptide
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros

Legal Events

Date Code Title Description
FB Suspension of granting procedure